LEADER 04614nam 2201069z- 450 001 9910557595503321 005 20231214133445.0 035 $a(CKB)5400000000043722 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68283 035 $a(EXLCZ)995400000000043722 100 $a20202105d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aCharacterization and Clinical Management of Dilated Cardiomyopathy 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 electronic resource (232 p.) 311 $a3-03943-761-5 311 $a3-03943-762-3 330 $aDilated cardiomyopathy (DCM) is a particular phenotype of non-ischemic systolic heart failure, frequently recognizing a genetic background and affecting relatively young patients with few comorbidities. Nowadays, long-term survival of DCM patients has been markedly improved due to an early diagnosis and uninterrupted and tailored follow-up under constant optimal medical and non-pharmacological evidence-based treatments. Nevertheless, DCM is still one of the most common causes of heart transplantation in the western world. Clinical management requires an integrated and systematic use of diagnostic tools and a deeper investigation of the basic mechanisms underlying the disease. However, several emerging issues remain debated. Specifically, the genotype?phenotype correlation, the role of advanced imaging techniques and genetic testing, the lack of appropriate risk stratification models, the need for a multiparametric and multidisciplinary approach for device implantation, and a continuous reclassification of the disease during follow-up remain challenging issues in clinical practice. Therefore, the aim of this Special Issue is to shed the light on the most recent advancements in characterization and clinical management of DCM in order to unveil the conundrum of this particular disease. 606 $aMedicine$2bicssc 610 $aSCN5A 610 $acardiac sodium channel 610 $acardiac channelopathy 610 $adilated cardiomyopathy 610 $aprecision medicine 610 $aarrhythmias 610 $aatrial fibrillation 610 $acardiomyopathy 610 $aheart failure 610 $asupraventricular arrhythmia 610 $asystolic dysfunction 610 $atachycardiomyopathy 610 $aventricular arrhythmia 610 $aleft atrial strain 610 $acardiac resynchronization therapy 610 $amuscular dystrophy 610 $acalcium 610 $aheart 610 $agene therapy 610 $aphospholamban 610 $aSerca2a 610 $amdx 610 $aoxidative stress 610 $amembrane stabilization 610 $aleft ventricular noncompaction 610 $acongenital heart disease 610 $acongestive heart failure 610 $anon-ischemic cardiomyopathy 610 $agenetics 610 $adesmin 610 $amitochondrial dysfunction 610 $amyopathy 610 $awhole exome sequencing 610 $alaminopathy 610 $aLMNA 610 $abiomarkers 610 $atroponin T 610 $aNT-proBNP 610 $amalignant ventricular arrhythmia 610 $aarrhythmic risk stratification 610 $aDNA methylation 610 $aalternative splicing 610 $aepigenetics 610 $anonischemic dilated cardiomyopathy 610 $acardiac magnetic resonance imaging 610 $alate gadolinium enhancement 610 $along axis strain 610 $aleft ventricle sphericity index 610 $amajor adverse cardiovascular events 610 $asex differences 610 $aleft ventricular reverse remodelling 610 $along-term outcomes 610 $aleft ventricle non-compaction cardiomyopathy 610 $acardiac magnetic resonance 610 $atitin 610 $aRNA binding motif protein 20 (RBM20) 610 $asarcomere 610 $adiastolic dysfunction 610 $aphosphorylation 610 $anon-sense mRNA decay 610 $amammalian target of rapamycin (mTOR) complex-1 610 $aduchenne muscular distrophy 615 7$aMedicine 700 $aMerlo$b Marco$4edt$01292384 702 $aMerlo$b Marco$4oth 906 $aBOOK 912 $a9910557595503321 996 $aCharacterization and Clinical Management of Dilated Cardiomyopathy$93022238 997 $aUNINA